Functional characterization of p53 in nasopharyngeal carcinoma by stable shRNA expression

International Journal of Oncology

Volumn 34, Issue 4, 2009, Pages 1017-1027

  Sun, Yi ^a,b   Yi, Hong ^a   Yang, Yixuan ^a   Yu, Yanhui ^a   Ouyang, Yongmei ^a   Yang, Fang ^a,b   Xiao, Zhiqiang ^a   Chen, Zhuchu ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Central South University   (China)

Author keywords

Nasopharyngeal carcinoma; P53; RNAi; ShRNA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN MDM2; PROTEIN P53; SHORT HAIRPIN RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENOTOXICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RNA INTERFERENCE;

ANIMALS; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MICE; MICE, INBRED BALB C; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; RNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649445782     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000227     Document Type: Article

References (48)

1. Licitra L, Bernier J, Cvitkovic E, Grandi C, Spinazze S, Bruzzi P, Gatta G and Molinari R: Cancer of the nasopharynx. Crit Rev Oncol Hematol 45: 199-214, 2003.
2. Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005.
3. Jeyakumar A, Brickman TM, Jeyakumar A and Doerr T: Review of nasopharyngeal carcinoma. Ear Nose Throat J 85: 168-184, 2006.
4. Ferlay J, Bray F, Pisani P and Parkin DM: GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC Cancer Base No. 5. IARC Press, Lyon, 2001.
5. Raab-Traub N: Epstein-Barr virus in the pathogenesis of NPC. Cancer Biol 12: 431-441, 2002.
6. Chang ET and Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777, 2006.
7. Jalbout M, Bel Hadj Jrad B, Bouaouina N, Gargouri J, Yacoub S, Zakhama A, Khlifa R and Chouchane L: Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma. Int J Cancer 101: 146-150, 2002.
8. Oren M: Decision making by p53: life, death and cancer. Cell Death Differ 10: 431-442, 2003.
9. Prives C and Hall PA: The p53 pathway. J Pathol 187: 112-126, 1999.
10. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
11. Spruck CH III, Tsai YC, Huang DP, Yang AS, Rideout WM III, Gonzalez-Zulueta M, Choi P, Lo KW, Yu MC and Jones PA: Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 52: 4787-4790, 1992.
12. Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P, Tursz T, Liu E and Raab-Traub N: Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66: 3768-3775, 1992.
13. Bachouchi M, Cvitkovic E, Azli N, Gasmi J, Cortes-Funes H,. Boussen H, Rahal M, Kalifa C, Schwaab G, Eschwege F, Wibault P and Armand JP: High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. J Natl Cancer Inst 82: 616-620, 1990.
14. Ganly I, Soutar DS, Brown R and Kaye SB: p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. Br J Cancer 82: 392-398, 2000.
15. Niedobitek G, Agathanggelou A, Barber P, Smallman LA, Jones EL and Young LS: p53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 170: 457-461, 1993.
16. Sheu LF, Chen A, Tseng HH, Leu FJ, Lin JK, Ho KC and Meng CL: Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol 26: 380-386, 1995.
17. Chow LW, Khoo US, Yuen APW and Wei WI: Expression of p53 in recurrent nodal metastasis from nasopharyngeal carcinoma (NPC). Eur J Surg Oncol 23: 415-418, 1997.
18. Roychowdhury DF, Tseng A Jr, Fu KK, Weinberg V and Weidner N: New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and c-erbB2 expression. Cancer 77: 1419-1426, 1996.
19. Shao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX and Hu LF: Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res 24: 2309-2318, 2004.
20. Wang LF, Chai CY and Kuo WR: The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma. Acta Otolaryngol 126: 769-774, 2006.
21. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate interference in cultured mammalian cells. Nature 411: 494-498, 2001.
22. Sun Y, Yi H, Zhang PF, Li MY, Li C, Li F, Peng F, Feng XP, Yang YX, Yang F, Xiao ZQ and Chen ZC: Identification of differential proteins in nasopharyngeal carcinoma cells with p53 silence by proteome analysis. FEBS Lett 581: 131-139, 2007.
23. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)). Methods 25: 402-408, 2001.
24. Tamura K, Southwick EC, Kerns J, Rosi K, Carr BI, Wilcox C and Lazo JS: Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res 60: 1317-1325, 2000.
25. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
26. Colombel M, Filleur S, Fournier P, Merle C, Guglielmi J, Courtin A, Degeorges A, Serre CM, Bouvier R, Clezardin P and Cabon F: Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 65: 300-308, 2005.
27. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW and Weichselbaum RR: Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 86: 10104-10107, 1989.
28. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordan J, Cena V and Llopis J: Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279: 8976-8985, 2004.
29. Bosari S and Viale G: The clinical significance of p53 aberrations in human tumors. Virchows Arch 427: 229-241, 1995.
30. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL and Barbareschi M: Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 9: 151-1599, 1996.
31. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B and Klijn JG: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60: 2155-2162, 2000.
32. Kawasaki M, Nakanishi Y, Kuwano K, Yatsunami J, Takayama K and Hara N: The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced nonsmall cell lung cancer. Clin Cancer Res 3: 1195-1200, 1997.
33. Quon H, Liu FF and Cummings BJ: Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 23: 147-159, 2001.
34. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL and Fouret P: p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18: 385-394, 2000.
35. Genc E, Hosal AS, Gedikoglu G, Ozyar E and Sozeri B: Prognostic value of p53, proliferating cell nuclear antigen, and Ki-67 expression in undifferentiated nasopharyngeal carcinomas. Otolaryngol Head Neck Surg 122: 868-873, 2000.
36. Faccioli S, Cavicchi O, Caliceti U, Rinaldi Ceroni A and Chieco P: Cell proliferation as an independent predictor of survival for patients with advanced nasopharyngeal carcinoma. Mod Pathol 10: 884-894, 1997.
37. Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O'Sullivan B, Cummings BJ, Warde P and Liu F-F: Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 94: 1997-2006, 2002.
38. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ and Chan AT: Prognostic significance of tumor angiogenesis, Ki-67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma - a prospective study. Head Neck 25: 864-872, 2003.
39. Scheffner M, Werness BA, Huibregtse JM, Levine A and Howley P: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136, 1990.
40. Lechner M, Mack D, Finicle A, Crook K, Vousden K and Laumins L: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated expression of transcription. EMBO J 11: 3045-3052, 1992.
41. Yew P and Berk A: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357: 82-85, 1992.
42. Zhang Q, Cutsch D and Kenny S: Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 14: 1929-1938, 1994.
43. Momand J, Sambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69: 1237-1245, 1992.
44. Cheung FM, Pang SW, Yau TK, Chow SK and Lo KW: Nasopharyngeal intraepithelial lesion: Latent Epstein-Barr virus infection with malignant potential. Histopathology 45: 171-179, 2004.
45. Murono S, Yoshizaki T, Park CS and Furukawa M: Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology 34: 432-438, 1999.
46. Fries KL, Miller WE and Raab-Traub N: Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 70: 8653-8659, 1996.
47. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, Wang WB and Chen JY: Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 23: 2531-2539, 2004.
48. Li L, Guo L, Tao Y, Zhou S, Wang Z, Luo W, Hu D, Li Z, Xiao L, Tang M, Yi W, Tsao SW and Cao Y: Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Lett 255: 219-231, 2007.